硕贝德(300322) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥392,283,469.71, a decrease of 18.81% compared to ¥483,192,912.85 in the same period last year[3] - Net profit attributable to shareholders was ¥2,731,107.42, down 75.99% from ¥11,374,982.17 year-on-year[3] - The company reported a basic earnings per share of ¥0.01, a decrease of 50.00% from ¥0.02 in the same period last year[3] - Total operating revenue for Q1 2022 was CNY 392,283,469.71, a decrease of 18.8% compared to CNY 483,192,912.85 in the same period last year[19] - The company's net profit for Q1 2022 was CNY 4,961,079.40, significantly lower than CNY 19,443,205.38 in Q1 2021, indicating a decline of 74.5%[19] - The total comprehensive income for Q1 2022 was CNY 2,532,453.62, down from CNY 15,325,949.99 in the same period last year[21] Cash Flow and Liquidity - The net cash flow from operating activities improved to ¥67,618,432.11, a significant increase of 171.99% compared to -¥93,921,658.67 in the previous year[3] - Operating cash flow for Q1 2022 was CNY 67,618,432.11, a recovery from a negative cash flow of CNY -93,921,658.67 in Q1 2021[24] - The net cash flow from financing activities for Q1 2022 was CNY 36,259,370.89, down from CNY 77,652,429.15 in Q1 2021[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,900,619,526.97, reflecting a slight increase of 0.09% from ¥2,897,922,685.19 at the end of the previous year[3] - Current assets totaled CNY 1,825,661,446.84, slightly down from CNY 1,847,202,801.85, a decrease of 1.2%[18] - Total liabilities decreased to CNY 1,466,086,406.48 from CNY 1,466,920,007.25, a reduction of 0.6%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,838[10] - The number of shares held by the top shareholder, Tibet Shobeyde Holdings Co., Ltd., is 78,825,104, accounting for 16.92% of total shares[11] - The total number of restricted shares increased to 26,383,821 from 23,903,814, reflecting a rise of approximately 10.3%[13] Investment and Expenses - The company reported a significant reduction in investment cash outflows, with cash paid for investments decreasing by 93.10% to ¥3,000,000.00 from ¥43,500,000.00 in the previous year[8] - Research and development expenses for Q1 2022 were CNY 31,614,551.17, compared to CNY 30,432,864.79 in the previous year, an increase of 3.9%[19] - The company incurred a total operating expense of CNY 483,482,472.59 in Q1 2022, down from CNY 638,787,626.69 in Q1 2021[24] Government Support and Financial Health - Government subsidies recognized during the period amounted to ¥16,954,380.08, an increase of 2159.38% compared to ¥750,400.41 in the same period last year[8] - The company's financial health appears stable, with a focus on managing receivables and enhancing cash flow for future investments[15] Future Outlook - The company plans to continue exploring market expansion opportunities and new product development in the upcoming quarters[14]